G

Genedrive PLC
LSE:GDR

Watchlist Manager
Genedrive PLC
LSE:GDR
Watchlist
Price: 2.275 GBX -9%
Market Cap: 12.4m GBX
Have any thoughts about
Genedrive PLC?
Write Note

Genedrive PLC
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genedrive PLC
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
G
Genedrive PLC
LSE:GDR
Depreciation & Amortization
ÂŁ259k
CAGR 3-Years
70%
CAGR 5-Years
-37%
CAGR 10-Years
3%
Oxford Nanopore Technologies PLC
LSE:ONT
Depreciation & Amortization
ÂŁ41.6m
CAGR 3-Years
34%
CAGR 5-Years
46%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Depreciation & Amortization
ÂŁ4.8m
CAGR 3-Years
81%
CAGR 5-Years
110%
CAGR 10-Years
N/A
Ergomed PLC
LSE:ERGO
Depreciation & Amortization
ÂŁ5.5m
CAGR 3-Years
9%
CAGR 5-Years
21%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Depreciation & Amortization
ÂŁ361k
CAGR 3-Years
-10%
CAGR 5-Years
14%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Depreciation & Amortization
ÂŁ3.2m
CAGR 3-Years
7%
CAGR 5-Years
51%
CAGR 10-Years
55%
No Stocks Found

Genedrive PLC
Glance View

Market Cap
12.4m GBX
Industry
Life Sciences Tools & Services

Genedrive Plc is a holding company, which engages in the development of drugs and disease diagnostics. The Company’s Genedrive device is a molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company’s commercial products include Genedrive MT-RNR1, Genedrive BioPlex, Genedrive HCV ID Kit and Genedrive 96 SARS-CoV-2 Ki. Genedrive MT-RNR1 is a commercial test for antibiotic induced hearing loss. Genedrive BioPlex is developed for the determination of military biothreats from pathogens. Genedrive HCV ID Kit is effective in the diagnosis of Hepatitis C Virus (HCV) infection in resource limited settings. Genedrive 96 SARS-CoV-2 Ki is a plate format of a COVID-19 molecular test for high throughput use, which detects all known variants of COVID-19.

GDR Intrinsic Value
0.42 GBX
Overvaluation 82%
Intrinsic Value
Price
G

See Also

What is Genedrive PLC's Depreciation & Amortization?
Depreciation & Amortization
259k GBP

Based on the financial report for Dec 31, 2023, Genedrive PLC's Depreciation & Amortization amounts to 259k GBP.

What is Genedrive PLC's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
3%

Over the last year, the Depreciation & Amortization growth was 1%. The average annual Depreciation & Amortization growth rates for Genedrive PLC have been 70% over the past three years , -37% over the past five years , and 3% over the past ten years .

Back to Top